European Companies Search Engine
EU funding (€5,978,245): Personalised Medicine by Predictive Modeling in Stroke for better Quality of Life Hor1 May 2018 EU Research and Innovation programme "Horizon"
Overview
Text
Personalised Medicine by Predictive Modeling in Stroke for better Quality of Life
Stroke is one of the most severe medical problems with far-reaching public health and socio-economic impact, gathering momentum in an ageing society. PRECISE4Q sets out to minimise the burden of stroke for the individual and for society. It will create multi-dimensional data-driven predictive simulation computer models enabling – for the first time – personalised stroke treatment, addressing patient’s needs in four stages: prevention, acute treatment, rehabilitation and reintegration. Heterogeneous data from multidisciplinary sources will be integrated: genomics, microbiomics, biochemical; imaging including mechanistic biophysiological models of brain perfusion/function; social, lifestyle, gender; economic and worklife, requiring substantial efforts for information extraction, semantic labelling and standardisation. Novel hybrid model architectures, structured prediction models, complex deep-learning and gradient boosting models will form the Digital Stroke Patient Platform including a Stroke Risk CDSS (Clinical Decision Support System), Treatment Outcomes CDSS, Rehab Programme, Socio-Economic Planning Tool and New QvidLab. The decision support will be tailored to the patient's current life stage thus enabling clinicians to optimise prevention and treatment strategies over time, and will include personalised coping strategies, support of well-being and reintegration into social life and work. The predictive capability and clinical precision will be validated with real clinical data generated by (i) prospective clinical studies and (ii) retrospective analyses of big data sets: health registries, cohort studies, health insurance data, electronic health records. PRECISE4Q will have a clinically measurable and sustainable impact leading to better understanding of risk, health and resilience factors. In contrast to current schematic therapy guidelines, it will support patients throughout their life-long journey by personalised strategies for their specific needs.
Funded Companies:
| Company name | Funding amount |
| AOK Nordost - DIE Gesundheitskasse | €78,750 |
| Charite - Universitaetsmedizin Berlin | €1,316,250 |
| Deutsches Forschungszentrum FUR Kunstliche Intelligenz GmbH | €281,250 |
| Eidgenoessische Technische Hochschule Zuerich | €467,205 |
| Empirica Gesellschaft FUR Kommunikations UND Technologieforschung mbH | €567,750 |
| Fundacio Institut Guttmann | €377,190 |
| Linkopings Universitet | €454,225 |
| Medizinische Universitat Graz | €240,688 |
| Qmenta Imaging SL | €392,500 |
| Tartu Ulikool | €366,250 |
| Technological University Dublin | €1,005,000 |
| Universidad de Murcia | €157,438 |
| University College Dublin, National University of Ireland, Dublin | €273,750 |
Source: https://cordis.europa.eu/project/id/777107
The filing refers to a past date, and does not necessarily reflect the current state.